The Insider: Meet the CEOs Webcast Replay
We were joined by the CEOs of exciting ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.
- (ASX: PTX) Prescient Therapeutics Limited – Steven Yatomi-Clarke
- (ASX: AMX) Aerometrex – Chris Mahar
Recorded on 28th September 2022 at 12pm (AEST).
FEATURED SPEAKERS
Steven Yatomi-Clarke
CEO and Managing Director - Prescient Therapeutics Limited (ASX: PTX)
Prescient Therapeutics is a clinical-stage oncology company focused on developing next-generation personalised cancer therapies within the total global US$280 billion (2021) oncology industry. The company has collaborated with the world-leading Peter Mac cancer centre to develop a next-generation OmniCAR cell therapy that is capable of reshaping cancer treatment. In September 2022, Prescient teamed up with the largest cancer centre in the US, MD Anderson, aiming to create best-in-class cancer therapies to treat haematological malignancies. The company’s PTX-100 and PTX-200 targeted cancer therapies are continuing their progress on encouraging clinical results.
Chris Mahar
CFO - Aerometrex (ASX: AMX)
Aerometrex is a professional aerial mapping business, specialising in aerial imagery, photogrammetry, LiDAR, 3D modelling and aerial imagery subscription services. The company’s tech has won numerous awards for its work across Australia, the US and Europe and supports the NSW Government’s world-first digital planning tool – Land iQ. At the end of FY22, Aerometrex realised a 168.9% increase in EBITDA to $7.07 million, record revenue ($25.03 million) and several key milestones such as its largest off-the-shelf data sale ($2.58 million) to the Australian Government. Recently, the company was awarded a package of work to be undertaken in the Pilbara region on behalf of Australian mining giant Rio Tinto.
Reach Corporate provide Corporate Advisory Services to Wellnex Life and have been engaged by them to manage their investor communications.
